[go: up one dir, main page]

PE20080521A1 - DERIVADOS DE ESPIROCETAL DE ANILLO FUSIONADO COMO INHIBIDORES DEL COTRANSPORTADOR Na+-GLUCOSA 2 (SGLT2) - Google Patents

DERIVADOS DE ESPIROCETAL DE ANILLO FUSIONADO COMO INHIBIDORES DEL COTRANSPORTADOR Na+-GLUCOSA 2 (SGLT2)

Info

Publication number
PE20080521A1
PE20080521A1 PE2007000972A PE2007000972A PE20080521A1 PE 20080521 A1 PE20080521 A1 PE 20080521A1 PE 2007000972 A PE2007000972 A PE 2007000972A PE 2007000972 A PE2007000972 A PE 2007000972A PE 20080521 A1 PE20080521 A1 PE 20080521A1
Authority
PE
Peru
Prior art keywords
spirocetal
sglt2
inhibitors
glucose
carrier
Prior art date
Application number
PE2007000972A
Other languages
English (en)
Inventor
Tsutomu Sato
Yoshihito Ohtake
Masahiro Nishimoto
Takashi Emura
Takamitsu Kobayashi
Marina Yamaguchi
Kyouko Takami
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38981587&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080521(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of PE20080521A1 publication Critical patent/PE20080521A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE ESPIROCETAL DE ANILLO FUSIONADO DE FORMULA (I) DONDE R1, R2, R3 Y R4 SON CADA UNO H, ALQUILO(C1-C6) OPCIONALMENTE SUSTITUIDO CON Ra, O ARALQUILO(C7-C14) OPCIONALMENTE SUSTITUIDO CON Rb O C(=O)Rx, DONDE Ra ES HALOGENO, OH, CN, NITRO, ENTRE OTROS; Rb ES HALOGENO, OH, CN, CARBOXI, ENTRE OTROS; Rx ES ALQUILO(C1-C6), ALCOXI(C1-C6), ENTRE OTROS; n ES 1 O 2; Ar ES UN COMPUESTO DE FORMULA (c), (d), ENTRE OTROS, DONDE Re ES ARALQUILO(C7-C14) O HETEROARILALQUILO(C5-C12); W ES S, O U NRh, DONDE Rh ES H O ALQUILO(C1-C6). SON COMPUESTOS PREFERIDOS: (3'R,4'S,5S,5'S,6'R)-3-[(4-ETILFENIL)METIL]-6'-HIDROXIMETIL-3',4',5',6'-TETRAHIDRO-ESPIRO[TIENO[2,3,f]ISOBENZOFURAN-5(7H),2'-[2H]PIRAN]-3',4',5'-TRIOL, (3'R,4'S,5'S,6'R,7S)-1-[(4-ETILFENIL)METIL]-6'-HIDROXIMETIL-3',4',5',6'-TETRAHIDRO-ESPIRO[FURO[3,4,f]INDOL-7(5H),2'-[2H]PIRAN]-3',4',5'-TRIOL, (1S,3'R,4'S,5'S,6'R)-8-[(4-ETILFENIL)METIL]-3,3',4,4',5',6'-HEXAHIDRO-6'-HIDROXIMETIL-ESPIRO[2-OXA-9-TIA-FLUORENO-1,2'-[2H]PIRAN]-3',4',5'-TRIOL, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DEL COTRANSPORTADOR Na+-GLUCOSA 2 (SGLT2) SIENDO UTILES EN EL TRATAMIENTO DE DIABETES, HIPERGLUCEMIA, OBESIDAD
PE2007000972A 2006-07-27 2007-07-26 DERIVADOS DE ESPIROCETAL DE ANILLO FUSIONADO COMO INHIBIDORES DEL COTRANSPORTADOR Na+-GLUCOSA 2 (SGLT2) PE20080521A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006205242 2006-07-27

Publications (1)

Publication Number Publication Date
PE20080521A1 true PE20080521A1 (es) 2008-06-13

Family

ID=38981587

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000972A PE20080521A1 (es) 2006-07-27 2007-07-26 DERIVADOS DE ESPIROCETAL DE ANILLO FUSIONADO COMO INHIBIDORES DEL COTRANSPORTADOR Na+-GLUCOSA 2 (SGLT2)

Country Status (18)

Country Link
US (1) US8207134B2 (es)
EP (1) EP2048152A4 (es)
JP (1) JP5165565B2 (es)
KR (1) KR20090033911A (es)
CN (1) CN101495494A (es)
AR (1) AR062110A1 (es)
AU (1) AU2007277704A1 (es)
BR (1) BRPI0715248A2 (es)
CA (1) CA2658921A1 (es)
CL (1) CL2007002186A1 (es)
IL (1) IL196585A0 (es)
MX (1) MX2009000579A (es)
NO (1) NO20090173L (es)
PE (1) PE20080521A1 (es)
RU (1) RU2009106866A (es)
TW (1) TWI432446B (es)
WO (1) WO2008013277A1 (es)
ZA (1) ZA200900706B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4260770B2 (ja) 2005-05-09 2009-04-30 任天堂株式会社 ゲームプログラムおよびゲーム装置
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
BRPI0918841B8 (pt) 2008-08-28 2021-05-25 Pfizer derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais, composições farmacêuticas e usos
SI2496583T1 (sl) 2009-11-02 2015-02-27 Pfizer Inc. Derivati dioksa-biciklo(3.2.1)oktan-2,3,4-triola
AR079438A1 (es) 2009-12-09 2012-01-25 Panacea Biotec Ltd Derivados de azucar, composiciones farmaceuticas y sus usos
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
ITMI20110362A1 (it) * 2011-03-09 2012-09-10 F I S Fabbrica Italiana Sint P A Procedimento per la preparazione di 1-(6-metilpiridin-3-il)-2-[4-(metilsolfonil)fenil]etanone, un intermedio dell'etoricoxib.
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP2014530186A (ja) 2011-09-13 2014-11-17 パナセア バイオテック リミテッド 新規ｓｇｌｔ阻害剤
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN104987314A (zh) * 2015-07-14 2015-10-21 佛山市赛维斯医药科技有限公司 含苯并异恶唑和末端硝基苄基类结构的化合物及其用途
CN105001174A (zh) * 2015-07-14 2015-10-28 佛山市赛维斯医药科技有限公司 含苯并异恶唑和末端腈基苄基类结构的化合物及其用途
CN110483476B (zh) * 2019-08-15 2020-11-27 绍兴文理学院 一种催化法制备苯并硒吩类化合物的工艺
CN110483475B (zh) * 2019-08-15 2020-11-27 绍兴文理学院 一种氧化银催化法制备苯并噻吩类化合物的方法
CN112574226A (zh) * 2020-12-15 2021-03-30 海门华祥医药科技有限公司 5,6-亚甲基二氧基吲哚的制备方法
CN116178143B (zh) * 2021-11-26 2024-10-01 中国科学院大连化学物理研究所 一种1,4-萘二甲酸/酯、1,4-萘二甲酸衍生物及其制备方法和应用
CN117050126A (zh) * 2023-08-15 2023-11-14 南京华威医药科技集团有限公司 一种新的托格列净关键异构体制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470845A (en) 1992-10-28 1995-11-28 Bristol-Myers Squibb Company Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
JP2000080041A (ja) 1998-03-09 2000-03-21 Tanabe Seiyaku Co Ltd 医薬組成物
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6627611B2 (en) 2000-02-02 2003-09-30 Kotobuki Pharmaceutical Co Ltd C-glycosides and preparation of thereof as antidiabetic agents
HUP0300057A3 (en) 2000-03-17 2003-09-29 Kissei Pharmaceutical Glucopyranosyloxy benzylbenzene derivatives, pharmaceutical compositions containing the same and intermediates for the preparation of the derivatives
ATE318272T1 (de) 2001-04-11 2006-03-15 Bristol Myers Squibb Co Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren
DE10231370B4 (de) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
TWI254635B (en) 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof
TWI309980B (en) 2003-03-14 2009-05-21 Yamanouchi Pharma Co Ltd C-glycoside derivatives or salts thereof
US7094763B2 (en) 2003-08-01 2006-08-22 Janssen Pharaceutica, N.V. Substituted fused heterocyclic C-glycosides
AR048282A1 (es) * 2003-08-01 2006-04-19 Janssen Pharmaceutica Nv Indol- o - glucosidos sustituidos
US7094764B2 (en) * 2003-08-01 2006-08-22 Janssen Pharmaceutica N.V. Substituted benzimidazole-, Benztriazole-, and benzimidazolone-O-glucosides
PT1651658E (pt) * 2003-08-01 2013-03-07 Mitsubishi Tanabe Pharma Corp Novos compostos que possuem actividade inibidora dirigida contra os transportadores dependentes do sódio
RS20060320A (sr) * 2003-08-01 2008-08-07 Janssen Pharmaceutica N.V., Supstituisani indazol-o-glukozidi
NZ549629A (en) 2004-03-04 2010-06-25 Kissei Pharmaceutical Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
EP1724277A4 (en) 2004-03-04 2012-05-02 Kissei Pharmaceutical ACCOLE HETEROCYCLIC DERIVATIVE, DRUG-CONTAINING COMPOSITION THEREOF, AND THE USE THEREOF
DK1730131T3 (da) 2004-03-16 2012-08-13 Boehringer Ingelheim Int Glucopyranosyl-substituerede benzol-derivater, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåder til deres fremstilling
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
DE102004034690A1 (de) 2004-07-17 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
JP2008508213A (ja) 2004-07-27 2008-03-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄ−グルコピラノシル−フェニル置換環状体、そのような化合物を含有する医薬品、それらの使用及びその製造方法
WO2006018150A1 (de) 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
DE102004048388A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EP1813611B1 (en) * 2004-11-18 2014-10-01 Kissei Pharmaceutical Co., Ltd. 1-substituted-3- beta-d-glycopyranosylated nitrogenous hetero- cyclic compounds and medicines containing the same
TW200637869A (en) * 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
WO2007140191A2 (en) * 2006-05-23 2007-12-06 Theracos, Inc. Glucose transport inhibitors and methods of use
US7795228B2 (en) * 2006-12-28 2010-09-14 Theracos, Inc. Spiroheterocyclic glycosides and methods of use

Also Published As

Publication number Publication date
WO2008013277A1 (en) 2008-01-31
CL2007002186A1 (es) 2008-02-01
IL196585A0 (en) 2009-11-18
KR20090033911A (ko) 2009-04-06
RU2009106866A (ru) 2010-09-10
AR062110A1 (es) 2008-10-15
JPWO2008013277A1 (ja) 2009-12-17
US20100234609A1 (en) 2010-09-16
US8207134B2 (en) 2012-06-26
EP2048152A1 (en) 2009-04-15
TWI432446B (zh) 2014-04-01
AU2007277704A1 (en) 2008-01-31
ZA200900706B (en) 2010-05-26
JP5165565B2 (ja) 2013-03-21
TW200821323A (en) 2008-05-16
CN101495494A (zh) 2009-07-29
EP2048152A4 (en) 2013-01-23
MX2009000579A (es) 2009-01-27
NO20090173L (no) 2009-04-27
CA2658921A1 (en) 2008-01-31
BRPI0715248A2 (pt) 2013-06-04

Similar Documents

Publication Publication Date Title
PE20080521A1 (es) DERIVADOS DE ESPIROCETAL DE ANILLO FUSIONADO COMO INHIBIDORES DEL COTRANSPORTADOR Na+-GLUCOSA 2 (SGLT2)
PE20080731A1 (es) Derivados espirocetales comoinhibidores de sglt2
PE20091014A1 (es) Compuestos espiro y uso farmaceutico de los mismos
TN2009000199A1 (en) Heteromonocyclic compound and use thereof
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
PE20130155A1 (es) Derivados de ariletinilo
PE20080182A1 (es) Derivados pirrolo-quinoxalinona como antibacterianos
PE20020510A1 (es) DERIVADOS DE AZEPILO [4,5b] INDOLINA SUSTITUIDOS COMO LIGANDOS DE LOS RECEPTORES DE SEROTONINA (5-HT)
PE20141827A1 (es) Inhibidores de proteinas quinasas
AR053739A1 (es) Compuestos espiro condensados como inhibidores de la aldosterona sintasa
PE20060297A1 (es) Nuevos derivados fluoroglicosidicos de pirazoles como inhibidores de sglt 1
PE20141556A1 (es) Derivados de etinilo como moduladores alostericos de mglur5
MY152805A (en) Benzazepine derivatives useful as vasopressin antagonists
TW200720266A (en) Benzodioxane and benzodioxolan derivatives and uses thereof
PE20171640A1 (es) Analogos de nucleotidos sustituidos
PE20121158A1 (es) Derivados de feniletinilo como moduladores alostericos positivos (map)
AR065128A1 (es) Derivados de 2-aminooxazolinas como ligandos taar1. procesos de obtencion, composiciones farmaceuticas y usos
PE20061096A1 (es) Derivados de oxiindol como agonistas 5-ht4
PE20081831A1 (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona
PE20070793A1 (es) Compuestos triciclicos que contienen nitrogeno como agentes antibacterianos
PE20080941A1 (es) Compuestos triciclicos como agonistas del receptor de melatonina
ECSP088257A (es) Derivados de amida
AR041079A1 (es) Derivados de 2-ariltiazol como agonistas de receptores activados proliferadores de peroxisomas alfa y gamma (ppar alfa y gamma)
PE20090650A1 (es) Agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos
AR083166A1 (es) Derivados de alquil-piperazin-fenil 4(3h)-quinazolinonas utiles para tratar depresion, ansiedad, disfunciones sexuales femeninas y otras patologias del sistema nervioso central, y composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed